Asia
The cuts were apparently announced in late January with a WARN notice filed with the state.
Jing Medicine Technology will collaborate with ShanghaiTech University in a $100M partnership to discover and develop novel small molecule cancer drugs.
Luqa Pharma of Hong Kong closed a $15M Series B financing round led by Cenova Capital.
NetVation DL Medicine, a privately held Chengdu biotech, has entered a two-year research collaboration with Pfizer.
CR Pharma will be responsible for China clinical trials and other regulatory matters.
Late-stage data shows the use of Pfizer’s prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.
Shanghai’s C-Bridge Capital plans to raise $650M for its third healthcare PE fund, just six months after closing its second fund with $400M.
The shareholders of JHL Biotech voted to approve the company’s voluntary delisting from the Taiwan stock exchange.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
The company plans to raise $30 million by offering 4.3 million shares at a price range of $6 to $8.
PRESS RELEASES